These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30535008)

  • 21. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
    Van Stappen T; Vande Casteele N; Van Assche G; Ferrante M; Vermeire S; Gils A
    Gut; 2018 May; 67(5):818-826. PubMed ID: 28450388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Lucidarme C; Petitcollin A; Brochard C; Siproudhis L; Dewitte M; Landemaine A; Bellissant E; Bouguen G
    Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
    Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
    Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
    Roblin X; Boschetti G; Duru G; Williet N; Deltedesco E; Phelip JM; Peyrin-Biroulet L; Nancey S; Flourié B; Paul S
    Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease.
    Guiotto C; Daperno M; Frigerio F; Vizzini M; Cerruti R; Ercole E; Cosimato M; Lavagna A; Germano L; Migliardi M; Rocca R
    Dig Liver Dis; 2016 Feb; 48(2):138-43. PubMed ID: 26614644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TDM of Anti-TNF Agents: The Importance of Being Active!
    Annese V
    Inflamm Bowel Dis; 2020 Jan; 26(2):271-272. PubMed ID: 31247072
    [No Abstract]   [Full Text] [Related]  

  • 27. The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease.
    Sheasgreen C; Nguyen GC
    Curr Gastroenterol Rep; 2017 May; 19(5):19. PubMed ID: 28397129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
    Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
    Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab.
    Pouillon L; Ferrante M; Van Assche G; Rutgeerts P; Noman M; Sabino J; Vande Casteele N; Gils A; Vermeire S
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1276-1283.e1. PubMed ID: 29203225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.
    Dotan I; Ron Y; Yanai H; Becker S; Fishman S; Yahav L; Ben Yehoyada M; Mould DR
    Inflamm Bowel Dis; 2014 Dec; 20(12):2247-59. PubMed ID: 25358062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Success and safety of high infliximab trough levels in inflammatory bowel disease.
    Drobne D; Kurent T; Golob S; Svegl P; Rajar P; Terzic S; Kozelj M; Novak G; Smrekar N; Plut S; Sever N; Strnisa L; Hanzel J; Brecelj J; Urlep D; Osredkar J; Homan M; Orel R; Stabuc B; Ferkolj I; Smid A
    Scand J Gastroenterol; 2018 Aug; 53(8):940-946. PubMed ID: 29987967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proactive Versus Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: Is the Juice Worth the Squeeze?
    Franco DL; Click B
    Inflamm Bowel Dis; 2020 Jan; 26(1):112-113. PubMed ID: 31184363
    [No Abstract]   [Full Text] [Related]  

  • 36. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.
    Huang VW; Prosser C; Kroeker KI; Wang H; Shalapay C; Dhami N; Fedorak DK; Halloran B; Dieleman LA; Goodman KJ; Fedorak RN
    Inflamm Bowel Dis; 2015 Jun; 21(6):1359-67. PubMed ID: 25989340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?
    Orfanoudaki E; Drygiannakis I; Koutroubakis IE
    Aliment Pharmacol Ther; 2018 Nov; 48(9):1037-1038. PubMed ID: 30318690
    [No Abstract]   [Full Text] [Related]  

  • 39. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
    Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.